About idaptiq
idaptiq sells a software platform that automates the biostatistics work in clinical trials. It produces the documents regulators ask for, such as the statistical analysis plan, SDTM and ADaM datasets, and tables, listings and figures. Patient data never enters idaptiq's cloud and never passes through an LLM. It works directly with its biopharma and CRO customers.
The company is Idaptiq Trials Inc., based in Presque Isle, Michigan. Sandy Ferber Brine is founder and CEO. Nate Fox is co-founder and CTO. Adam Key leads biostatistics and statistical programming. Teri Karcher is an advisor, and Eric Roza is a key advisor.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 1, 2026 | Nov 2, 2026 | $2,790,000fully sold | 26 | $107K | Simple Agreements for Future Equity (SAFEs) and the equity securities issuable upon conversion of such SAFEsRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed idaptiq
idaptiq sells software that automates the biostatistics work in clinical trials. It is led by people who have worked in clinical trials for decades. It sells to biopharma companies and CROs. The company has not publicly named an investor.
The problem it targets
Biostatisticians and statistical programmers do a lot of manual, repeated work on every trial. idaptiq aims to cut those labor hours and speed up clinical trial activities. A protocol change often forces teams to redo downstream work.
What the product does
The platform takes the protocol, case report forms and database specifications. From them it produces the statistical analysis plan, SDTM and ADaM specifications and code, and the code for tables, listings and figures. A feature called idaptlinq links these deliverables. When a protocol amendment or other change comes in, it finds the work that depends on it. Humans review the output, and the platform meets GxP and Part 11 requirements.
We wrote this summary from public statements by idaptiq and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on idaptiq's Form D filed Nov 2, 2026.
